Saama and iNDX.Ai Launch New COVID-19 Command Center Analytics Platform To Expedite Clinical Research Efforts by Individual Sponsors

CAMPBELL, CA – (May 5, 2020) – Saama Technologies, Inc. (“Saama”), the #1 AI clinical analytics platform company, and iNDX.Ai, a leading Multi-omics Data Analytics and translational research platform company, today announced the launch of the new COVID-19 Command Center. The COVID-19 Command Center, based on a combination of Saama’s Life Science Analytics Cloud (LSAC) and iNDX.Ai’s iCore Platform, is a purpose-built, therapeutic area-specific data analytics platform that will accelerate the ability of life sciences companies to expedite internal research and development programs for therapies to prevent and treat COVID-19.

Many biopharma organizations are sharing COVID-19 research data through organizations such as the recently established EndPandemic National Data Consortium, which six companies – including Saama and iNDX.Ai – have joined. The COVID-19 Command Center was created to provide sponsors pursuing in-house COVID-19 clinical development efforts only with the same powerful, state-of-the-art, AI-powered data analytics platform being used by the EndPandemic National Data Consortium. The COVID-19 Command Center, includes patient data from ongoing COVID-19 clinical trials in China, South Korea, and the U.S. with nearly 8,500 patients, including over 3,000 positive cases. The COVID-19 Command Center delivers all the multiomics and clinical data analytics needed to manage COVID-19 clinical studies. From preclinical development to approval, researchers can optimize study design, patient selection, site activation and scientific analysis by dynamically visualizing, analyzing, and interrogating data faster than ever before.

“Saama wants all life science companies, whether they are engaged in public or private research efforts, to have access to the best possible analytics platform so they can expedite promising COVID-19 clinical trials and bring critical vaccines and treatments to the market as soon as possible,” said Suresh Katta, Founder and CEO of Saama Technologies. “The COVID-19 Command Center, the first offering from Saama’s purpose-built Command Center strategy, is customized to meet immediate needs related to research on the novel coronavirus, but can also be used more broadly for other infectious disease clinical development efforts now and in the future.”

“iNDX.Ai believes that AI-enabled, multi-modal deep and dense data analytics will help biopharma companies accelerate their translational research in clinical trials to deliver therapies that could potentially treat and prevent COVID-19,” said Mohan Uttarwar, CEO of iNDX.Ai. “The COVID-19 Command Center ensures that every life science company, whether engaged in solo or collaborative research, will be able to apply state-of-the-art data analytics to inform and advance their research and help end the pandemic. By partnering on the COVID-19 Command Center, iNDX.Ai and Saama provide an end-to-end clinical development solution, from in silico biomarker discovery to Investigational New Drug (IND) application submission.”

Learn more about using the purpose-built COVID-19 Command Center to optimize COVID-19 clinical research.

About LSAC
Life Science Analytics Cloud (LSAC) is the leading AI-powered clinical analytics platform that seamlessly integrates, curates, and animates clinical trial data, delivering more actionable insights for faster decision making.

About iCore
iCore is an innovative informatics platform which delivers novel insights and accelerates the drug development process for precision medicine.

About Saama Technologies, Inc.

Saama is the #1 AI clinical analytics platform company, enabling the life sciences industry to conduct faster and safer clinical development and regulatory programs. Today, over 50 biotech companies use Saama’s award-winning Life Science Analytics Cloud (LSAC) platform on more than 1,500 studies, including many of the top 20 pharmaceutical companies. LSAC’s rich applications facilitate an unprecedented, authoritative oversight of comprehensive clinical research data, enabling companies to file New Drug Applications (NDAs) more efficiently and bring drugs to market faster. Discover more at and follow Saama @SaamaTechInc.

About iNDX Technology, Inc.

iNDX.Ai is a Silicon Valley-based data analytics company that has developed iCore, an innovative informatics platform that delivers novel insights and accelerates the drug development process for precision medicine. We are a highly motivated team of entrepreneurs, doctors, engineers, and data scientists with a mission to develop innovative software products that can help our collaborators find a cure for disease like cancer and COVID-19 and make a global societal impact. The genomics revolution has created a data tsunami. We have developed a novel approach for managing immuno-oncology clinical trials and translational research. Our offerings enable users to aggregate, analyze, visualize, interrogate & correlate biomedical data and gather strategic and predictive insights. For more information visit


Media Contact
Gregory T. Simpson
Saama Technologies
[email protected]